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Abstract
Annexin 1 (ANXA1) is a Ca
2C- and phospholipid-binding
protein that plays an important role as a mediator of
glucocorticoid action in the host-defence and neuroendocrine
systems. Sex differences in hypothalamo–pituitary–adrenal
(HPA) axis activity are well documented and a number of
studies have demonstrated that gonadalsteroids act asregulators
ofHPAactivity.Theaimofthisstudywastoinvestigatetheeffect
ofovariectomyand17b-estradiolreplacement,andestrouscycle
stage, on anterior pituitary ANXA1 content. The amount of
anterior pituitary ANXA1 determined by western blotting
varied with estrous cycle stage with a peak at estrus declining
to a trough at proestrus. Ovariectomy resulted in a signiﬁcant
(P!0.05) decrease in anterior pituitary ANXA1 content.
Administration of 17b-estradiol (1 mg/100 g) signiﬁcantly
(P!0.01) increased anterior pituitary ANXA1 expression
intheovariectomized animals.Incontrast,therewas nochange
in pituitary ANXA1 content in response to 17b-estradiol in
adrenalectomized and adrenalectomized/ovariectomized rats.
Treatment of TtT/GF cells, a folliculo-stellate cell line, with
17b-estradiol (1.8–180 nM) increased ANXA1 mRNA
expression and increased the amount of ANXA1 protein
externalized in response to a dexamethasone stimulus. These
resultsindicatethat17b-estradiolstimulatesANXA1expression
intheanterior pituitaryandinvivoanadrenalfactorcontributes
to the mechanism of action.
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Introduction
Sex differences in hypothalamo–pituitary–adrenal axis (HPA)
activity are well documented and a number of studies have
demonstrated that gonadal steroids act as regulators of HPA
activity (Viau & Meaney 1991, Freeman 1994, Carey et al.
1995). Changes in plasma corticosterone are associated with
estrous cycle stage in rodents such that peak adrenocortico-
trophichormone (ACTH) andcorticosterone levelsarehighest
in the afternoon of proestrus (Carey et al. 1995), the time of
maximal estradiol secretion (Freeman 1994). In addition, the
stress responsiveness of the female HPA varies with the estrous
cycle, with increased corticosterone release in response to stress
occuring at proestrus (Viau & Meaney 1991). Sexual
dimorphism in corticosterone secretion is well established:
female rodents displayelevated corticosterone secretion in basal
and some stress conditions relative to males (Critchlow et al.
1963). Furthermore, estrogen exerts stimulatory effects on
stress-induced ACTH and glucocorticoid release, whereas
testosterone acts to inhibit HPA activity (Seale et al. 2004). In
addition, it is now evident that exposure to gonadal steroids
inﬂuences HPA programming during perinatal development
(Seale et al. 2005) and is responsiblefor the changes in the HPA
responsiveness at puberty (Viau et al. 2005).
Annexin 1 (ANXA1) is a member of the annexin family of
Ca
2C- and phospholipid-binding proteins (Moss & Morgan
2004) that has been demonstrated to act as a mediator of
glucocorticoidaction in the inﬂammation and in the controlof
anterior pituitaryhormonerelease(Johnetal.2004).Functional
studies have demonstrated a key role for ANXA1 in mediating
certain acute, non-transcriptional inhibitory actions of the
glucocorticoids on the release of ACTH (Taylor et al. 1995,
1997) and other pituitary hormones (reviewed in John et al.
2004).Theeffectof glucocorticoidsin several tissues,including
the anterior pituitary, is to cause externalization of ANXA1
from the cytoplasm to the outer cell surface where it is retained
bya Ca
2C-dependentmechanism(Chapmanetal.2002)andto
induce ANXA1 synthesis (Philip et al. 2001). ANXA1 is
expressedstronglyintheS100-positivefolliculo-stellatecells(FS
cells) in the anterior pituitary (Traverso et al. 1999)a n din vivo
almost total loss of FS cell ANXA1 immunoreactivityoccurs in
adrenalectomizedratswhichisreplenisheduponglucocorticoid
replacement(Ozawaetal.2002).Functionalandbindingstudies
suggest that the glucocorticoid-induced translocation of
ANXA1 via the ATP-binding cassette transporter ABCA1
(Chapman et al. 2003, Omer et al. 2006) is an important
mechanismwhich enables the proteintoaccessbinding sites on
the surface of the endocrine cells and thereby exert paracrine
regulation on the release of ACTH and other pituitary
hormones via surface binding proteins (Christian et al. 1997).
The role of ANXA1 has so far been studied almost
exclusively in male rodents and it is not known how ANXA1
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estrogen status. Our recent ﬁndings demonstrate that
ANXA1 null mice exhibit sexual dimorphisms in HPA
function and inﬂammatory responses (Hannon et al. 2003,
Morris et al. 2006). The occurrence of gender-based
differences in the susceptibility to a number of disease models
in the rodent (Schuurs & Verheul 1990, Homo-Delarche et al.
1991, Whitacre et al. 1998) has been attributed to complex
interactions between the differential HPA axis activity and the
immune system of male and female rats. In human subjects, a
strong correlation exists between serum cortisol concen-
trations and ANXA1 expression in peripheral blood
leukocytes (Mulla et al. 2005). Mulla et al. (2005) proposed
that changes in leukocyte ANXA1 expression in human
subjects may serve as an index of tissue sensitivity to
glucocorticoids, and that such changes might contribute to
autoimmune and inﬂammatory diseases associated with
glucocorticoid dysregulation. It is therefore possible that
gonadal regulation of ANXA1 expression may be of
physiological signiﬁcance in contributing to the etiology of
the sexual dimorphisms in neuroendocrine and host-defence
function and susceptibility to disease. In the present study, we
have investigated the hypothesis that 17b-estradiol regulates
ANXA1 expression in the anterior pituitary. We now report
(1) the effects of ovariectomy and 17b-estradiol replacement
in female rats, and (2) the effects of 17b-estradiol in a FS cell
line, on ANXA1 expression.
Materials and Methods
Drugs
The following drugs were used: 17b-estradiol, dexamethasone
sodium phosphate, and corticotropin releasing factor (CRF).
17b-estradiol (E2) was dissolved directly in sesame oil for invivo
s.c. injection. Dexamethasone (Faulding Pharmaceutical plc,
Leamington Spa, Warks, UK) and corticotrophin-releasing
hormone (CRH; Bachem, Heidelberg, Germany) used in
in vitro experiments were diluted directly into the incubation
medium.AlldrugsandreagentswerefromSigmaChemicalCo.
unless otherwise stated.
Animals
AdultfemaleSprague–Dawleyrats(200 g)werepurchasedfrom
Harlan Olac (Bicester, Oxon, UK) and were allowed to
acclimatize for 2 weeks in the animal holding facility before
experimentation. The Universities Federation for Animal
Welfare (UFAW) Handbook on the Care and Management of
Laboratory Animalswas followed andthe study wascarried out
under license in accordance with the UK Animals (Scientiﬁc
Procedures)Act1986.Theratswerehousedingroupsofﬁveper
cage in a quiet room with 14 h light:10 h darkness and
temperature maintained at 20–21 8C; food was available ad
libitum. All experiments were started between 0800 and 1000 h
to avoid changes associated with the circadian rhythm. For
estrouscyclestudies,ratsweresmeareddailyfor30daysbetween
0800 and 1000 h. The smears were collected on glass slides,
stained with toluidine blue, and examined under a light
microscope. The cycle stage was estimated and only rats
observedtobecyclingregularlywerechosenforstudy(nZ6rats
used per cycle stage). Animals were killed by stunning and
decapitation and the anterior pituitary glands removed. Trunk
blood was collected and placed in chilled heparinized tubes for
centrifugalseparation(2000 g,10 min)ofplasmaforsubsequent
assay of corticosterone. The uteri were weighed postmortem
andinallcasesweightswerefoundtocorrelatewiththestageof
the estrous cycle.
Rat ovariectomy and treatment with 17b-estradiol
Adult female Sprague–Dawley rats (200 g) were anesthetized
with Hypnorm/Hypnovel (1:1:2 dilutionin water, 3 ml/kg ip;
Janssen Pharmaceuticals, Oxford, UK) and subsequentlyeither
sham-operated (control) or bilaterally ovariectomized (OVX).
In further experiments, subgroups of rats were bilaterally
adrenalectomized(ADX),OVX,orbilaterallyADXandOVX.
Theanimalswere allowedtorecover postoperatively for7 days,
andonday8aftersurgerygroupsofrats(nZ6rats)receivedas.c.
injection of vehicle (sesame oil), or 17b-estradiol (1 mg/100 g
body weight), 24 and 12 h before sacriﬁce on day 9. The
concentrationandregimen of17b-estradioltreatment has been
reported in the literature to produce physiological concen-
trations of plasma 17b-estradiol (163 pg/ml) in the Sprague–
Dawleyrats(Young etal.2001).Animalswerekilledbystunning
and decapitation and the anterior pituitary glands removed.
Trunk blood was collected and placed in chilled heparinized
tubes for centrifugal separation (2000 g, 10 min) of plasma for
subsequent assay of ACTH and corticosterone. Uteri were also
removed and weighed.
Detection of ANXA1 by SDS-PAGE and western blot analysis
ANXA1wasextractedfrompituitarytissueandTtT/GFcellsby
sonication (25 Hz, 20 s, Soniprep 150, MSE, Crawley, UK) on
ice in EDTA (10 mM) containing Triton X-100 (1% v/v) as
described previously (Chapman et al. 2003). The protein
content of each sample was determined using the Pierce BCA
proteinassay(Pierce,Macclesﬁeld,Cheshire,UK).Thesamples
werethenanalyzedforANXA1bySDS-PAGEandsubsequent
western blotting using a well-characterized polyclonal anti-
ANXA1antibody(raisedinsheepagainstthefull-lengthhuman
recombinant ANXA1 and diluted in the ratio of 1:10 000;
Chapmanetal. 2003) asaprobe. Normalizationwas conducted
by gently striping the blots (0.2 M glycine (pH 2.8), 1 h, room
temperature) and re-blocking and re-probing with a mouse
b-actinantibody(1:10 000,1 h,room temperature)andmouse
secondary antibody (1:5000, 1 h, room temperature; both
AbCam, Cambridge, UK). Intensity values were normalized
relativetocontrolvalues.Theblotswerescannedusingaﬂatbed
scanner (HP Scanjet 5200 with Adobe Photodeluxe Business
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software program (TINA version 2.10, Raytest Isotopenmess-
geraete GmbH, Straubenhardt, Germany).
Secretion of ACTH in vitro by anterior pituitary segments
Rat anterior pituitary segments from (1) OVX- and
17b-estradiol-treated OVX females or (2) proestrus and
estrus females were distributed randomly (1 segment/well) in
the wells of 24-well tissue culture plates (Costar, Cambridge,
MA, USA) and incubated at 37 8C for 90 min in 1 ml
incubation medium (1% (vol/vol) aprotonin (Bayer Corp.,
Saffron Walden, Essex, UK) and 1% (vol/vol) penicillin/-
streptomycin in oxygenated Earles’ Balanced Salt Solution
(pH 7.4); phenol red-free) under a humidiﬁed atmosphere
saturated with 95% O2,5 %C O 2. The medium was changed
after 1 and 1.5 h. The segments were then incubated for a
further 1 h in medium containing CRH (10 nM); controls
were exposed to an equal volume (1 ml) of medium alone.
Where appropriate dexamethasone (0.1 mM) was included in
the medium throughout both the pre- and ﬁnal incubation
periods. Medium from the ﬁnal incubation was collected and
stored in aliquots (300 ml, K20 8C) for subsequent measure-
ment of immunoreactive (ir) ACTH.
ACTH ELISA and corticosterone RIA
ACTH was determined in duplicate by use of a commercially
available ELISA (IDS Ltd, Boldon Colliery, Tyne and Wear,
UK) according to the manufacturer’s instructions. The assay
sensitivity was 0.5 pg/ml and the inter- and intraassay
coefﬁcients of variation were 5.8 and 3.1% respectively.
Corticosterone was determined in duplicate by the use of a
commercially available RIA (IDS Ltd) according to the
manufacturer’s instructions. The minimum detection level of
the assay was 0.39 ng/ml and the intra- and interassay
coefﬁcients of variation were 10.4 and 12.4% respectively.
Dilution of samples provided a parallel displacement to the
standards in both assays.
TtT/GF cell incubations
FS-like(TtT/GF)cellsweremaintainedasdescribedpreviously
(Tierney et al. 2003) in a humidiﬁed incubator at 37 8C, 5%
CO2 and cultured in Dulbecco’s modiﬁed Eagle medium
(DMEM) DMEM-Hams-F12 medium (Invitrogen Ltd.),
enriched with 15% (v/v) fetal calf serum (PAA Laboratories
Ltd., Yeovil, Somerset, UK), penicillin (100 U/ml), and
streptomycin(100 mg/ml)ina5%CO2humidiﬁedatmosphere.
Plates (24 well) containing approximately 50 000 cells/well
were allowed to reach 80% conﬂuence. The cells were then
incubated either in incubation medium alone (1% (vol/vol)
aprotonin (Bayer Corp.) and 1% (vol/vol) penicillin/strepto-
mycin in oxygenated Earles’ Balanced Salt Solution (pH 7.4)
phenolred-free)orwithgradedconcentrationsof17b-estradiol
(0.18–1800 nM) for 24 h. The duration of treatment of 24 h
was initially selected as previous ANXA1 promoter-driven
luciferase reporter gene studies in TtT/GF cells have
demonstrated increased luciferase expression in 24 h (Solito
et al. 2003). In further time-course experiments, TtT/GF cells
were exposed to 17b-estradiol (18 nM) for 3, 6, 12, or 24 h. In
addition, TtT/GF cells were incubated for 24 h either in
medium alone, 17b-estradiol (18 nM) alone, dexamethasone
(0.1 mM) alone, or co-treated with 17b-estradiol (18 nM) and
dexamethasone(0.1 mM).Attheendofeachincubation,period
cells were processed for western blot analysis of total ANXA1
expression. In order to investigate the effects of 17b-estradiol
pretreatment on dexamethasone-induced externalization of
ANXA1, control- and 17b-estradiol (18 nM, 24 h)-treated
groupsweresubsequentlyincubatedfor3 heither inincubation
medium alone or with 0.1 mM dexamethasone sodium
phosphate. Thedurationof3-htreatmentwithdexamethasone
is well established to stimulate ANXA1 externalization (Taylor
et al. 1997, Chapman et al. 2003). At the end of the incubation
period, cells were processed for western blot analysis of cell
surface and intracellular ANXA1 expression. Cell surface
ANXA1 was removed from the outer cell membranes by
washing the tissue gently for 2 min in a solution containing
1m ME D T Ai nP B S( 0 .05 M(pH7.4);OxoidChemicalsLtd.,
Basingstoke, Hants, UK) which, by chelating Ca
2C, releases
ANXA1 into the medium from Ca
2C-dependent cell surface
binding sites.
Detection of estrogen receptor (ER)a and ERb in TtT/GF cells
by immunoﬂuorescence microscopy
For immunoﬂuorescence experiments, TtT/GF cells were
seeded into eight-well glass chamber slides (Nalge Nunc
International, Cambridge, UK)at adensityof5000 cells/well.
Thecellswereeither incubatedinmediumaloneorstimulated
with 180 nM estradiol for 24 h, then ﬁxed in 3% paraformal-
dehyde, 0.05% glutaraldehyde (5 min), and permeabilized
with0.2%TritonX-100(inPBSatroomtemperature,5 min).
Non-speciﬁc antibody binding sites were blocked with block
buffer(3%BSAinPBS;PBS–BSA)for30 min.Theexpression
of ERa was detected with a mouse monoclonal anti-ERa
(prediluted,usedneat;Dako,Ely,Cambs,UK)andERbwitha
rabbit polyclonal ERb antibody (1:100; Oncogene, Notting-
ham, UK) overnight at 4 8C in PBS–BSA. Immunoreacted
sections were then washed with PBS and incubated for 1 h at
room temperaturewith ﬂuorescein-conjugated anti-mouse or
anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA).
The chambers were rinsed with PBS and the nuclei counter-
stainedfor5 minwithTOPRO-3(MolecularProbes,Eugene,
OR, USA). Slides were mounted in Vectashield mounting
medium (Vector Laboratories) and examined using a titanium
crystal sapphire (TCS) confocal microscope (Leica Corp.
Microsystems, Wetzlar GmbH, Germany). Non-speciﬁc
staining and background were assessed by substitution of
non-immune sera for primary antisera and incubation with
ERa and ERb antibodies previously absorbed with an excess
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Real-time PCR
Total RNAwas isolated from pituitary tissue or TtT/GF cells
using the RNeasy kit (Qiagen) following the manufacturer’s
instructions and treated with DNA-free DNAse (Ambion,
Witney, UK) to remove traces of genomic DNA contami-
nation. Three micrograms of tRNA from each sample were
subsequently reverse transcribed using 1 ml Moloney murine
leukemia virus reverse transcriptase (Clontech), 2 ml1 0m M
dNTP, 2 ml 100 mM dithiothreitol in a total volume of 20 ml.
To measure cDNA levels, a threshold cycle (Ct) was selected
within the exponential phase of the ampliﬁcation for all
standards and samples. Standards were generated by serial
dilutions of a cDNA pool from rat pituitary. A standard curve
was generated by plotting standards against Ct values and
sample values were read from this standard curve. ANXA1
expressionwasthendetectedandquantiﬁedbyreal-timePCR
(QPCR) in 25 ml reactions containing 12.5 ml Absolute
QPCR mix (ABgene, Epsom, Surrey, UK), 0.4 mM of each
of the ANXA1 primers (For primer 50ATACAGATGCC-
AGGGCTTTGTATGA30; Rev primer 50TGGGATGTCT-
AGTTTCCACCACACA30), and 0.25 mM ANXA1 FAM/
TAMRA-dual-labeled probe (Sigma-Genosys) in a 96-well
plate format. The QPCR assay was performed in an ABI
PRISM 7700 (Applied Biosystems, Warrington, Cheshire,
UK) and cycled as follows: initial enzyme activation at 95 8C
for 15 min then 40 cycles of 95 8C for 15 s and 60 8C for
1 min. The assays were normalized relative to an endogenous
control, 18S rRNA (primers and probes from Applied
Biosystems) and the results expressed as the amount of
ANXA1 mRNA/18SRNA.
Data analysis
Semi-quantitative measures of ANXA1 protein expression
were made by comparisons of western blot band optical
densities (arbitrary units) to give a relative numerical guide to
the ratios of the band intensities normalized to actin and their
variance. Responses to steroids were calculated as a
percentage of the corresponding vehicle control and
expressed as the meanGS.E.M.( nZ3 gels); statistical
comparisons between the normally distributed data from
groups were made by ANOVA. Each of the studies was
repeated thrice, and in all instances the data proﬁle was
similar. For hormone release studies, preliminary analysis by
the Shapiro and the Wilkes test conﬁrmed that the data were
normally distributed. Subsequent analysis was done by
ANOVA with post hoc comparisons by Scheffe’s test. Since
the rate of basal ACTH release in vitro varied between
experiments, statistical comparisons were made within
experiments only. Differences were considered signiﬁcant if
P was !0.05.
Results
Effect of ovariectomy and 17b-estradiol replacement on anterior
pituitary ANXA1 expression
In order to investigate the regulation of anterior pituitary
ANXA1 content by 17b-estradiol in vivo, female rats were
sham-operated or ovariectomized and treated with either
vehicle or 17b-estradiol (1 mg/100 g body weight (BW);
24 h) and anterior pituitary ANXA1 measured by western
blot analysis. ANXA1 was readily detectable in female
anterior pituitary tissue by western blot analysis as a 37 K
molecular bandwhich corresponded to the nativebiologically
active species of the protein. Western blot analysis demon-
strated a signiﬁcant (P!0.01) reduction in anterior pituitary
ANXA1 total content following ovariectomy compared with
sham-operated (Fig. 1A: OVX shown in western blot lanes 1
and 2 compared with sham-operated shown in lanes 3 and 4;
densitometry shown in Fig. 1C). 17b-Estradiol treatment of
OVX females for 24 h caused a signiﬁcant (P!0.01) increase
in anterior pituitary ANXA1 content (Fig. 1A, 17b-estradiol-
treatedOVX lanes 5and 6 versusvehicle-treated OVXlanes 1
and 2; Fig. 1C). Similarly, 17b-estradiol treatment of sham-
operated females for 24 h also caused a signiﬁcant (P!0.01)
increase in anterior pituitary ANXA1 content (Fig. 1A,
17b-estradiol-treated sham-operated lanes 7 and 8 versus
vehicle-treated sham-operated lanes 3 and 4; Fig. 1C). No
change was observed in the amount of b-actin detected
(Fig. 1B). Circulating corticosterone was signiﬁcantly
reduced (P!0.05) in OVX compared with sham-operated
female rats (Fig. 1D) and in OVX animals corticosterone was
signiﬁcantly increased (P!0.01) in response to 17b-estradiol
(Fig. 1D). No signiﬁcant difference in circulating corticos-
terone was measured in sham-operated animals treated with
17b-estradiol (Fig. 1D) compared with vehicle. The basal
corticosterone levels were high in these experiments and it is
possible that the animals were stressed during the testing
conditions. Surgery and treatments were indicated to have
been effective as the uterine weights of the OVX rats
were signiﬁcantly (P!0.01) lower than sham-operated, and
17b-estradiol treatment of OVX rats caused a signiﬁcant
increase (P!0.05) in uterine weight such that there was no
signiﬁcant difference compared with the sham-operated
uterine weights (Fig. 1E).
Effect of adrenalectomy and combined adrenalectomy and
ovariectomy on the stimulation of anterior pituitary ANXA1
expression by 17b-estradiol
In order to examine the potential role of the adrenal in the
regulatory effects of 17b-estradiol on ANXA1 expression in
OVX rats, the effect of adrenalectomy was investigated.
Administrationof17b-estradiol(1 mg/100 g)toOVXanimals
induced a signiﬁcant (P!0.05) increase in anterior pituitary
ANXA1 mRNA (Fig. 2A) and protein (Fig. 2B) compared
with vehicle-treated controls. As expected, adrenalectomy
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Figure 1 Western blots showing the effect of ovariectomy and replacement 17b-estradiol (E2) treatment
for 24 h on pituitary ANXA1 content; (A) shows ANXA1, (B) shows b-actin loading control. Vehicle-
treatedOVX,lanes1and2;vehicle-treatedsham-operated,lanes3and4;E2-treatedOVX,lanes5and6;
E2-treated sham-operated, lanes 7 and 8. (C) Histogram showing integrated densitometry data; open
columns, vehicle-treated; and ﬁlled columns, E2-treated. Values are expressed as meansGS.E.M., nZ6
animals.*P!0.01versussham-operated;
†P!0.01versusrespectivevehicle-treated,ANOVA.(DandE)
The effect of ovariectomy and replacement with E2 for 24 h on (D) serum corticosterone and (E) uterine
weightsinfemalerats.Opencolumns,vehicle-treated;ﬁlledcolumns,E2-treated.Valuesareexpressedas
meansGS.E.M., nZ6 animals.
‡P!0.05 versus sham vehicle;
§P!0.01 versus OVX vehicle; NS, not
signiﬁcant versus sham vehicle; ANOVA plus Scheffe’s test.
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ANXA1 mRNA (Fig. 2A) and protein (Fig. 2B) compared
with OVX. Administration of 17b-estradiol to ADX and
ADX/OVX females did not alter the expression of ANXA1
mRNA or protein (Fig. 2A and B). Measurement of
corticosterone (Fig. 2C) demonstrated that concentrations
were signiﬁcantly (P!0.05) elevated in 17b-estradiol-treated
OVX animals compared with vehicle-treated OVX and
conﬁrmed the effectiveness of ADX.
Western blot analysis of ANXA1 expression during the
estrous cycle
ANXA1 was measured by western blot analysis in anterior
pituitary glands from female rats in each estrous cycle stage in
order to investigate alterations in ANXA1 protein content in
the estrous cycle. Figure 3 illustrates the effect of the estrous
cycle on anterior pituitary ANXA1 content. Typical western
blots are shown in Fig. 3A–D and densitometry data in
Fig. 3E–F. The amount of ANXA1 in anterior pituitary
(Fig. 3A and E) began to reduce at metestrusOdiestrus and
was signiﬁcantly reduced by approximately a ﬁvefold
reduction at proestrus (P!0.01 versus estrus; Fig. 3A
proestrus lanes 7 and 8 versus estrus lanes 1 and 2). However,
no change was observed in the amount of b-actin detected
(Fig. 3B). The ANXA1 content of male anterior pituitary was
intermediate to that of proestrus and estrus females (Fig. 3C
and E) and no difference was observed in b-actin levels
(Fig.3D). Measurement of corticosterone demonstrated
highest circulating concentrations at proestrus and lowest
concentrations at estrus as previously reported (Fig. 3F; Carey
et al. 1995).
Regulation of ANXA1 by 17b-estradiol in TtT/GF cells
In order to explore the possibility of direct actions of 17b-
estradiol on ANXA1 expression in FS cells, the effects of
graded concentrations of 17b-estradiol (0.18–1800 nM) on
ANXA1 mRNA and protein content in the TtT/GF FS cell
line were investigated. Initial immunoﬂuorescence
microscopy studies localized the subcellular distribution of
ERa and ERb in TtT/GF cells (Fig. 4). In control- and
17b-estradiol-treated (24 h, 180 nM) conditions, strong
immunoﬂuorescent staining for ERa (Fig. 4A–F) and ERb
(Fig. 4G–L) was localized to the nucleus with weaker
immunoﬂuorescence extended throughout the cytoplasm.
No non-speciﬁc immunolabeling was detected in absorbed
antibody controls (Fig. 4M and N). The effects of incubating
TtT/GF cells for 24 h with increasing concentrations of
17b-estradiol (0.18–1800 nM) on the amount of ANXA1
mRNA and protein are shown in Fig. 5. Real-time PCR
assay of ANXA1 mRNA in TtT/GF cells conﬁrmed that the
positive control stimulus dexamethasone (0.1 mM, 24 h)
produced a signiﬁcant (P!0.05) increase in ANXA1
mRNA and revealed that 17b-estradiol (1.8–180 nM, 24 h)
caused a concentration-dependent increase in ANXA1
mRNA (Fig. 5A). In contrast, western blot analysis
demonstrated no signiﬁcant effect of graded concentrations
of 17b-estradiol (0.18–1800 nM, 24 h; Fig. 5B and C) and no
signiﬁcant effect of 17b-estradiol (18 nM) treatment for
various periods(0–24 h; Fig. 5D) onANXA1 protein content
in TtT/GF cells. However, pretreatment of TtT/GF cells
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Figure 2 Histograms illustrating the effect of OVX, ADX, and
OVX/ADX and 17b-estradiol treatment in female rats on (A) anterior
pituitary ANXA1 mRNA, measured by real-time PCR, (B) anterior
pituitary ANXA1 protein, measured by western blot analysis, and
(C) blood corticosterone. Open columns, vehicle-treated; ﬁlled
columns, 17b-estradiol-treated. Values are expressed as meansG
S.E.M., nZ6 animals. NS, not signiﬁcant versus corresponding
vehicle control; *P!0.05 versus vehicle-treated OVX,
†P!0.05
versus 17b-estradiol-treated OVX; ANOVA plus Scheffe’s test.
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Figure 3 Western blots showing anterior pituitary ANXA1 tissue content at estrus,
metestrus, diestrus, and proestrus in female rats; (A) shows ANXA1, (B) shows b-actin.
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males, lanes 3 and 4; proestrus, lanes 5 and 6. Histograms showing (E) integrated
densitometry data and (F) blood corticosterone measured at estrus, metestrus, diestrus,
and proestrus in female rats, and in male rats. Values are expressed as meansGS.E.M.,
nZ6 animals. *P!0.01,
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www.endocrinology-journals.org Journal of Endocrinology (2007) 192, 429–442Figure 4 Localization of ERa (A–F) and ERb (G–L) receptors in control- and 17b-estradiol (E2; 180 nM, 24 h)-
treatedTtT/GFcellsbyimmunoﬂuorescencemicroscopy.Figuresshowﬂuorescenceimagesoflabelingof:Aand
D, ERa; G and J, ERb; B, E, H and K, TO-PRO3 nuclear counterstain; C, F, I, L overlay of corresponding ER and
nuclear counterstain images. ERa, control (A–C), E2-treated (D–F); ERb, control (G–I), E2-treated (J–L). (M) ERa
preabsorbed antibody negative control, (N) ERb preabsorbed antibody negative control. Magniﬁcation, !250.
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increased the amount of surface ANXA1 detected in response
to dexamethasone-stimulated (0.1 mM, 3 h) externalization
(Fig. 6A, lanes 7 and 8 17b-estradiol and dexamethasone-
treated versus lanes 3 and 4 control- and dexamethasone-
treated; Fig. 6D), whereas the amount of intracellular
ANXA1 measured was unaffected (Fig. 6C and E). No
actin ir bands were detected in cell surface EDTA washes
(Fig. 6B) conﬁrming cell integrity. In subsequent experi-
ments, the effect of co-treatment of TtT/GF cells with
17b-estradiol (18 nM) and dexamethasone (0.1 mM) for 24 h
on ANXA1 content was measured (Fig. 7). Western blot
analysis conﬁrmed that dexamethasone alone signiﬁcantly
(P!0.05) increased ANXA1 content, whereas 17b-estradiol
treatment (18 nM) alone had no signiﬁcant effect (Fig. 7A,
lanes 1 and 2 control versus lanes 3 and 4 dexamethasone-
treated versus lanes 5 and 6 17b-estradiol-treated). However,
co-treatment of TtT/GF cells with 17b-estradiol (18 nM)
and dexamethasone (0.1 mM) for 24 h signiﬁcantly (P!0.05)
enhanced ANXA1 content compared with dexamethasone
treatment alone (Fig. 7A, lanes 7 and 8 dexamethasone and
17b-estradiol-treated versus lanes 3 and 4 dexamethasone
alone). However, no change was observed in the amount of
b-actin detected (Fig. 7B).
Dexamethasone inhibition of basal- and CRH-stimulated
ACTH release from pituitary segments in vitro
ANXA1 mediates certain acute inhibitory actions of the
glucocorticoids on ACTH release (Taylor et al. 1997). As
signiﬁcant differences in ANXA1 anterior pituitary content
were measured after 17b-estradiol treatment compared with
OVX, and in proestrus compared with estrus, we compared
the inhibitory effects of dexamethasone in vitro on basal and
stimulated ACTH release in these groups. The inhibitory
effects of dexamethasone (0.1 mM) on the release of ir-ACTH
induced by CRH (10 nM) from OVX- and 17b-estradiol-
treated OVX female pituitary segments in vitro is demon-
strated in Fig. 8A. No signiﬁcant difference in the basal release
of ir-ACTH or the signiﬁcant (P!0.01) increases in peptide
release induced by CRH were detected between OVX- and
17b-estradiol-treated OVX groups. However, a signiﬁcantly
greater inhibition (P!0.05) by dexamethasone of CRH-
stimulated ir-ACTH release was measured in OVX pituitary
segments compared with 17b-estradiol-treated OVX seg-
ments (Fig. 8A). Figure 8B similarly compares the inhibitory
effects of dexamethasone (0.1 mM) on the release of ir-ACTH
induced by CRH (10 nM) from anterior pituitary segments
from proestrus and estrus female rats. No signiﬁcant difference
in the basal release of ir-ACTH or the signiﬁcant (P!0.01)
increases in peptide release induced by CRH were detected
between proestrus and estrus pituitary segments. However, a
signiﬁcantly greater inhibition (P!0.05) by dexamethasone
of CRH-stimulated ir-ACTH release was measured in
proestrus compared with estrus segments (Fig. 8B).
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Figure 5 (A) Effect of 17b-estradiol (E2;1 .8–180 nM, 24 h) and
dexamethasone (Dex; 0.1 mM, 24 h) on the amount of ANXA1
mRNA in TtT/GF cells measured by quantitative PCR. Values
expressed as meansGS.E.M., nZ3 experiments *P!0.01 versus
negative control, ANOVA. (B) Effect of E2 (1.8–180 nM, 24 h) on the
amount of ANXA1proteinin TtT/GFcells. Western blot: lanes 1 and
2, control; lanes 3 and 4, 1.8n ME 2-treated; lanes 5 and 6, 18 nM
E2-treated; lanes 7 and 8, 180 nM E2-treated. (C) and (D) Integrated
densitometry data of the effects of (C) increasing concentrations of
E2 (0.18–1800 nM, 24 h) and (D) duration of treatment with 18 nM
E2 (3–24 h) on the amount of ANXA1 in TtT/GF cells. Open
columns, vehicle control; ﬁlled columns, 17b-estradiol-treated.
Values expressed as meansGS.E.M., nZ3 experiments; no signi-
ﬁcant differences measured versus control, ANOVA.
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To test the hypothesis that 17b-estradiol regulates ANXA1
expression, we measured pituitary ANXA1 content following
ovariectomyand17b-estradiolreplacementinrats.OVX-and
sham-operated rats were treated with a concentration of
17b-estradiol previously shown to mimic physiological levels
(Young et al. 2001). The uterine weight in 17b-estradiol-
treated OVX rats was not signiﬁcantly different to sham-
operatedratssuggestingthatnormalcirculatingconcentrations
of the hormone were restored. In OVX rats, the anterior
pituitary content of ANXA1 was signiﬁcantly reduced
compared with sham-operated controls and in both the
sham-operated and OVX animals 17b-estradiol replacement
caused a signiﬁcant increase in anterior pituitary ANXA1
content. Pituitary ANXA1 is expressed strongly in FS cells
(Traverso et al. 1999) and to date, glucocorticoids are the
principal factors known to stimulate ANXA1 synthesis in FS
cells(Ozawaetal.2002,Johnetal. 2004).Thepotenteffectsof
ovariectomyonHPAaxisactivityhavebeenwelldocumented
(Burgess&Handa1992,Careyetal.1995,Sealeetal.2004)and
consistent with these studies we found that ovariectomy
produced a signiﬁcant decrease in blood corticosterone that
was reversedbyadministration of17b-estradiol. 17b-Estradiol
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ﬁlledcolumns,17b-estradiol-treated;treatmentgroupisshownbelowthecolumns.ValuesexpressedasmeansG
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both directly and via modulation of glucocorticoid feedback
mechanisms(Peiffer&Barden1987,Peifferetal.1991,Burgess
& Handa 1992, Redei et al. 1994, Lo et al. 2000). It was
therefore possible that 17b-estradiol treatment increased the
amount of anterior pituitary ANXA1 expression via changes
in circulating glucocorticoid concentrations secondary to
estradiol treatment and/or via a direct pituitary action on
FS cells.
In order to test whether the 17b-estradiol-induced increase
in anterior pituitary ANXA1 content in vivo may be via
increased corticosterone release from the adrenal gland, 17b-
estradiol was administered to ADX and combined
OVX/ADX animals, and ANXA1 mRNA and protein
measured. 17b-Estradiol signiﬁcantly increased anterior
pituitary ANXA1 mRNA and protein content in the OVX
rats relative to vehicle OVX controls but no such increase
in response to 17b-estradiol was observed in the ADX or
double OVX/ADX groups. These ﬁndings show that in the
absence of the adrenal gland and circulating corticosterone,
17b-estradiol was unable to induce an increase in anterior
pituitary ANXA1 expression. An unexpected observation
was that combined ADX and OVX produced an increase in
ANXA1 expression, greater than in the adrenalectomy alone
groups. The ability of OVX to partially reduce the effects of
ADX on ANXA1 expression implies that gonadal steroids
may have inhibitory as well as permissive actions. It is
therefore possible that progesterone could also play a role in
the regulation of ANXA1 expression opposing the actions of
estrogen, which we are currently investigating.
Western blot analysis revealed that anterior pituitary
ANXA1 content varied with the estrous cycle. ANXA1
content was robustly decreased during proestrus and increased
in estrus. Estradiol concentrations vary with the rat estrous
cycle, being low at estrus, beginning to increase at late
metestrus, reaching a sharp peak at early afternoon of
proestrus from which levels start to decline by early evening
of proestrus. Corticosterone blood concentrations also vary
with the estrous cycle such that levels are highest in the
afternoon of proestrus (Carey et al. 1995), coinciding with the
time of maximal 17b-Estradiol secretion. One possible
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in estradiol during proestrus, and mediated via changes in
plasma corticosterone. However, it could also be that the
combination of estradiol and progesterone in proestrus drives
ANXA1 synthesis down and that the presence of estradiol in
the absence of progesterone during estrus increases ANXA1
synthesis. The abilityof OVX to partially reduce the effects of
ADX on ANXA1 expression supports the hypothesis that
gonadal steroids also have inhibitory actions. Although
estrogen treatment in male rats has been shown to either
induce (48 h treatment; Feldman et al. 1979) or reduce (72 h
treatment; Smith & Hammond 1992) corticosterone binding
globulin (CBG) production and secretion, CBG concen-
trations remain unchanged in estrogen-treated intact or OVX
female rats (up to 10 days treatment tested; Gala & Westphal
1965, 1966). Therefore, in the present study, it is unlikely that
24-h estrogen treatment induced changes in CBG that
contributed to the effects observed.
Although the promoter region of the ANXA1 gene lacks a
classical estrogen response element sequence, it does contain a
cAMP-responsive element through which dexamethasone
and estradiol have been shown to induce ANXA1 transcrip-
tion (Wallner et al. 1986, Horlick et al. 1991). Studies in a
human CCRF-CEM acute lymphoblastic leukemia cell line
have demonstrated that 17b-estradiol (at 1 mM) increases
ANXA1 mRNA synthesis and cell surface ANXA1
(Castro-Caldas et al. 2001) by a mechanism requiring AMP
response element (CRE)-binding protein (Castro-Caldas et
al. 2003). We therefore investigated the possibility of direct
effects of 17b-estradiol on ANXA1 expression in a FS cell
line. The TtT/GF cell line is a well-characterized pituitary
FS cell line, which closely models pituitary FS cells (Chapman
et al. 2003, Tierney et al. 2003, Omer et al. 2006). FS cells
express intracellular estrogen receptors (Mitchner et al. 1998)
and RT-PCR analysis has demonstrated the expression of
ERa and ERb mRNA in TtT/GF cells (Nagashima et al.
2003). By immunoﬂuorescence methods, we localized the
subcellular distribution of ERa and ERb in TtT/GF cells and
revealed that in control- and 17b-estradiol-treated conditions,
ERa and ERb were localized predominantly in the nucleus,
consistent with previous receptor localization studies in
gonadotropes (Sanchez-Criado et al. 2005). Treatment of
TtT/GF cells with 17b-estradiol stimulated an increase in
ANXA1 mRNA as measured by QPCR. No signiﬁcant
change in the amount of ANXA1 protein was measured in
response to the range of concentrations of 17b-estradiol
tested. However, the trend for estradiol regulation of ANXA1
protein expression was upward and it is not unusual for
protein changes to be smaller than mRNA changes as mRNA
and protein stoichiometry is not 1:1. It is well established that
glucocorticoids induce the expression and externalization of
ANXA1 in TtT/GF cells (Chapman et al. 2002, Omer et al.
2006). Pretreatment of TtT/GF cells with 17b-estradiol for
24 h increased the amount of ANXA1 synthesized and
externalized in response to a subsequent dexamethasone
stimulus compared with untreated controls. Furthermore,
co-treatment of cells with 17b-estradiol and dexamethasone
for 24 h enhanced pituitary ANXA1 protein content
compared with the response to dexamethasone alone.
Together, these results in a FS cell line suggest that 17b-
estradiol acts to enhance the production of ANXA1 mRNA
and release of ANXA1 in response to glucocorticoid.
However, in vivo 17b-estradiol did not inﬂuence ANXA1
mRNA or protein expression in ADX rats suggesting that
either 17b-estradiol does not have a direct effect in the rat
pituitary or the effect is inhibited by an unknown factor in
ADX conditions.
In the male anterior pituitary, ANXA1 plays a key role in
the manifestation of the early delayed feedback effects of
glucocorticoids (reviewed in John et al. 2004). We compared
the suppression of CRH-stimulated ACTH release by
dexamethasone in proestrus pituitary compared with estrus
and in OVX compared with estradiol-treated OVX tissue.
Suppression of CRH-stimulated ACTH release by dexa-
methasone produced signiﬁcantly greater inhibition in
proestrus pituitary compared with estrus and in OVX
compared with estradiol-treated OVX tissue. Therefore, in
conditions of greater pituitary ANXA1 expression and
greater estradiol exposure, the degree of glucocorticoid
suppression of ACTH release in vitro was less. These data
suggest that there is not a direct correlation between the
concentration of ANXA1 in the pituitary and the
glucocorticoid feedback inhibition. However, the ANXA1
antibody used in these studies does not discriminate between
the different phosphorylation states of ANXA1 and it may be
that the phosphorylation (or other modiﬁcation) of ANXA1
is a more important indicator of the functional action of
ANXA1 than the total quantity (Solito et al. 2006).
Conversely, in the female ANXA1 null mouse, basal HPA
parameters were not altered compared with wild type,
whereas in male ANXA1 null mice anterior pituitary
corticotrope number and ACTH content were increased
suggesting there may be a less critical role for ANXA1 in
females (Morris et al. 2006).
Sexual dimorphism in the immune and inﬂammatory
response in humans is well known. Females produce more
vigorous cellular and humoral reactions, are more resistant to
certain infections, and suffer a higher incidence of auto-
immune diseases (e.g. rheumatoid arthritis) than males
(Bouman et al. 2005). Disease expression is also inﬂuenced
by the reproductive status of the female. In ANXA1 null
mice, the male ANXA1 null leukocyte response to
experimental inﬂammation was enhanced to a greater extent
than the female response (Hannon et al. 2003). Our ﬁndings
demonstrating gender differences in ANXA1 expression may
therefore contribute to the gender differences underlying
susceptibility to autoimmune and inﬂammatory diseases.
In summary, 17b-estradiol treatment in vivo increased
ANXA1 expression in the anterior pituitary by a mechanism
that involves the adrenal gland. The parallel changes in
ANXA1 expression and in circulating corticosterone in
response to 17b-estradiol, suggest it is possible that
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estradiol. Further studies investigating the effects of a
glucocorticoid receptor antagonist, such as RU486, are
required to verify this possibility. The exact cell targets of
17b-estradiol action in vivo that lead to upregulation of
ANXA1 are unknown but could include indirect regulation
of brain,pituitary, and/or adrenal receptors or secretagogs that
inﬂuence corticosterone release or via a direct adrenal action
(Peiffer & Barden 1987, Peiffer et al. 1991, Burgess & Handa
1992, Lo et al. 2000). Experiments in TtT/GF cells indicate a
direct action of 17b-estradiol to enhance ANXA1 mRNA
content and externalization in response to glucocorticoid.
Together, these data are consistent with the hypothesis that
estrogens contribute to the regulation of pituitary ANXA1
expression and suggest that changes in ANXA1 may relate to
known gender differences in stress responsivity and suscep-
tibility to autoimmune and inﬂammatory diseases.
Acknowledgements
We thank Lynne Scott and Sarah Rodgers for expert technical
support.
Funding
This work was supported by the Wellcome Trust and there is
no conﬂict of interest that would prejudice its impartiality.
References
Bouman A, Heineman MJ & Faas MM 2005 Sex hormones and the immune
response in humans. Human Reproduction Update 11 411–423.
Burgess LH & Handa RJ 1992 Chronic-estrogen induced alterations in
adrenocorticotrophin and corticosterone secretion and glucocorticoid
receptor mediated functions on female rats. Endocrinology 131
1261–1269.
Carey MP, Deterd CH, deKoning J, Helmerhorst F & deKloet ER 1995 The
inﬂuence of ovarian steroids on hypothalamic–pituitary–adrenal regulation
in the female rat. Journal of Endocrinology 144 311–321.
Castro-Caldas M, Duarte CB, Carvalho AP & Lopes MCF 2001 Estradiol
promotes the synthesis and the secretion of annexin 1 in the CCRF-CEM
human cell line. Mediators of Inﬂammation 10 245–251.
Castro-Caldas M, Mendes AF, Duarte CB & Lopes MCF 2003 Dexametha-
sone-induced and estradiol-induced CREB activation and annexin 1
expression in CCRF-CEM lymphoblastic cells:evidence for the involve-
ment of cAMP and p38 MAPK. Mediators of Inﬂammation 12 329–337.
Chapman LP, Nishimura A, Buckingham JC, Flower RJ, Morris JF &
Christian HC 2002 Externalisation of annexin I from a folliculo-stellate,
TtT/GF, cell line. Endocrinology 143 4330–4338.
Chapman LP, Epton MJ, Buckingham JC, Flower RJ, Morris JF & Christian
HC 2003 Evidence for a role of the ATP-binding cassette transporter A1
(ABCA1) in the externalisation of annexin 1 from pituitary folliculostellate
cells. Endocrinology 144 1062–1073.
Christian HC, Taylor AD, Flower RJ, Morris JF & Buckingham JC 1997
Characterization and localization of lipocortin 1-binding sites on rat
anterior pituitary cells by ﬂuorescence-activated cell analysis/sorting and
electron microscopy. Endocrinology 138 5341–5351.
Critchlow V, Liebelt RA, Bar-Sela M, Mountcastle W & Lipscomb HS 1963
Sex difference in resting pituitary–adrenal function in the rat. American
Journal of Physiology 205 807–815.
Feldman D, Mondon CE, Horner JA & Weiser JN 1979 Glucocorticoid and
estrogen regulation of corticosteroid binding globulin production by the
liver. American Journal of Physiology 237 E493–E499.
Freeman M 1994 The neuroendocrine control of the ovarian cycle of the rat.
In The Physiology of Reproduction, edn 2, pp 111–149. Eds E Knobil &
JD Neill. New York: New York Press.
Gala RR & Westphal U 1965 Corticosteroid-binding globulin in the rat:
studies on the sex difference. Endocrinology 77 841–851.
Gala RR & Westphal U 1966 Further studies on the corticosteroid-
binding globulin in the rat: proposed endocrine control. Endocrinology
79 67–76.
Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ,
Gavins FN, Perretti M, Morris JF, Buckingham JC et al. 2003 Aberrant
inﬂammation and resistance to glucocorticoids in annexin 1 K/K mouse.
FASEB Journal 17 253–255.
Homo-Delarche F, Fitzpatrick F, Christeff N,Nunez EA,Bach JF& Dardenne
M 1991 Sex steroids, glucocorticoids, stress and autoimmunity. Journal of
Steroid Biochemistry 40 619–637.
Horlick KR, Cheng IC, Wong WT, Wakeland EK & Nick HS 1991 Mouse
lipocortin I gene structure and chromosomal assignment: gene duplication
and the origins of a gene family. Genomics 10 365–374.
John CD, Christian HC, Morris JF, Flower RJ, Solito E & Buckingham JC
2004 Annexin 1 and the regulation of endocrine function. Trends in
Endocrinology and Metabolism 15 103–109.
Lo MJ, Chang LL & Wang PS 2000 Effects of estradiol on corticosterone
secretion in ovariectomized rats. Journal of Cellular Biochemistry 77 560–568.
Mitchner NA, Garlick C & Ben-Jonathan N 1998 Cellular distribution and
gene regulation of estrogen receptors a and b in the rat pituitary gland.
Endocrinology 139 3976–3983.
Morris JF, Omer S, Davies E, Wang E, John CD, Afzal T, Wain S, Buckingham
JC, Flower RJ & Christian HC 2006 Lackof annexin 1 results in an increase
in corticotroph number in male but not female mice. Journal of
Neuroendocrinology 18 835–846.
Moss SE & Morgan RO 2004 The annexins. Genome Biology 5 219–227.
Mulla A, LeRoux C, Solito E & Buckingham JC 2005 Correlation between
the anti-inﬂammatory protein annexin 1 and serum cortisol in subjects with
normal and dysregulated adrenal function. Journal of Clinical Endocrinology
and Metabolism 90 557–562.
Nagashima AC, Giacomini D, Castro CP, Pereda MP, Renner U, Stalla GK &
Arzt E 2003 Transcriptional regulation of interleukin 6 in pituitary
folliculo-stellate cells. Molecular and Cellular Endocrinology 201 47–56.
Omer S, MeredithD, Morris JF & Christian HC 2006 Evidence for the role of
ABCA1 in the externalization of annexin 1 from pituitary folliculo-stellate
cells and ABCA1-transfected cell models. Endocrinology 147 3219–3227.
Ozawa H, Miyachi M, Ochiai I, Tsuchiya S, Morris JF & Kawata M 2002
Annexin 1 immunoreactivity in the folliculo-stellate cells of the rat anterior
pituitary: the effect of adrenalectomy and corticosterone treatment on its
subcellular distribution. Journal of Neuroendocrinology 14 621–628.
Peiffer A & Barden N 1987 Estrogen-induced decrease of glucocorticoid
receptor messenger ribonucleic acid concentration in rat anterior pituitary
gland. Molecular Endocrinology 1 435–440.
Peiffer A, Lapointe B & Barden N 1991 Hormonal regulation of type II
glucocorticoid receptor messenger ribonucleic acid in rat brain.
Endocrinology 129 2166–2174.
Philip JG, John CD, Cover PO, Morris JF, Christian HC, Flower RJ &
Buckingham JC 2001 Opposing inﬂuences of glucocorticoids and inter-
leukin-1betaonthesecretionofgrowthhormoneandACTHintheratinvivo:
role of hypothalamic annexin 1. British Journal of Pharmacology 134 887–895.
Redei E, Li L, Halasz I, McGivern RF & Aird F 1994 Fast glucocorticoid
feedback inhibition of ACTH secretion in the ovariectomized rat: effect of
chronic estrogen and progesterone. Neuroendocrinology 60 113–123.
Sanchez-Criado JE, Martin de las Mulas J, Bellido C, Aguilar R & Garrido-
Gracia JC 2005 Gonadotrope oestrogen receptor-a and -b and
Annexin 1 regulation by 17b-estradiol . E DAVIES and others 441
www.endocrinology-journals.org Journal of Endocrinology (2007) 192, 429–442progesterone receptor immunoreactivity after ovariectomy and exposure to
oestradiol benzoate, tamoxifen or raloxifene in the rat: correlation with LH
secretion. Journal of Endocrinology 184 59–68.
Schuurs AH & Verheul HA 1990 Effects of gender and sex steroids on the
immune response. Journal of Steroid Biochemistry 35 157–172.
Seale JV, Wood SA, Atkinson HC, Bate E, Lightman SL, Ingram CD, Jessop
DS & Harbuz MS 2004 Gonadectomy reverses the sexually diergic patterns
of circadian and stress-induced hypothalamo–pituitary–adrenal axis activity
in male and female rats. Journal of Neuroendocrinology 16 516–524.
Seale JV, Wood SA, Atkinson HC, Lightman SL & Harbuz MS 2005
Organizational role for testosterone and estrogen on adult hypothalamic–
pituitary–adrenal axis activity in the male rat. Endocrinology 146 1973–1982.
Smith CL & Hammond GL 1992 Hormonal regulation of corticosteroid-
binding globulin biosynthesis in the male rat. Endocrinology 130 2245–2251.
Solito E, Froud K, Christian H, Morris J & Buckingham J 2003 Effects
of dexamethasone and oestradiol on annexin 1 expression. Endocrine
Abstracts 6 P65.
Solito E, Christian HC, Festa M, Mulla A, Tierney T, Flower RJ &
Buckingham JC 2006 Post-translational modiﬁcation plays an essential role
in the translocation of annexin A1 from the cytoplasm to the cell surface.
FASEB Journal 20 E677–E687.
Taylor AD, Loxley HD, Flower RJ & Buckingham JC 1995 Immunoneu-
tralisation of lipocortin 1 reverses the acute inhibitory effects of
dexamethasone on the hypothalamo–pituitary adrenalocortical responses to
cytokines in the rat in vitro and in vivo. Neuroendocrinology 62 19–31.
Taylor AD, Christian HC, Morris JF, Flower RJ & Buckingham JC 1997 An
antisense oligodeoxynucleotide to lipocortin 1 reverses the inhibitory
actions of dexamethasone on the release of ACTH from rat pituitary tissue
in vitro. Endocrinology 138 2909–2918.
Tierney T, Christian HC, Solito E, Morris JF, Flower R & Buckingham JC
2003 The early delayed inhibitory action of glucocorticoids on ACTH
release is mediated by juxtacrine acting annexin 1 from folliculo-stellate
cells: evidence from a co-culture cell line model. Journal of Neuroendo-
crinology 15 1134–1143.
Traverso V, Christian HC, Morris JF & Buckingham JC 1999 Lipocortin 1
(annexin I): a candidate paracrine agent localized in pituitary folliculo-
stellate cells. Endocrinology 140 4311–4319.
Viau V & Meaney MJ 1991 Variations in the hypothalamic–pituitary–adrenal
response to stress during the estrous cycle in the rat. Endocrinology 129
2503–2511.
Viau V, Bingham B, Davis J, Lee P & Wong M 2005 Gender and puberty
interact on the stress-induced activation of parvocellular neurosecretory
neurons and corticotrophin-releasing hormone messenger ribonucleic acid
expression in the rat. Endocrinology 146 137–146.
Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK,
Foeller C, Chow EP, Browning JL, Ramachandran KL et al. 1986 Cloning
and expression of human lipocortin, a phospholipase A2 inhibitor with
potential anti-inﬂammatory activity. Nature 320 77–81.
Whitacre CC, Dowdell K & Griffen AC 1998 Neuroendocrine inﬂuences on
experimental autoimmune encephalomyelitis. Annals of the New York
Academy of Sciences 840 705–716.
Young EA, Altemus M, Parkison V & Shastry S 2001 Effects of estrogen
antagonists and agonists on the ACTH response to restraint stress in female
rats. Neuropsychopharmacology 25 881–891.
Received in ﬁnal form 13 November 2006
Accepted 15 November 2006
Made available online as an Accepted Preprint
17 November 2006
E DAVIES and others . Annexin 1 regulation by 17b-estradiol 442
Journal of Endocrinology (2007) 192, 429–442 www.endocrinology-journals.org